CATHI Joins with VSS to Launch World’s First Online Training Program for Endovascular Simulation

CATHI (Germany-based leading endovascular simulator supplier ) has joined forces with UK-based Vascular Simulation Solutions (VSS) to offer the world’s first on-line training masterclass using endovascular simulation coupled to a structured curriculum.

At its heart is the state-of-the-art CATHIS® simulator, which is fully functional with all standard software systems including every iOS system and Oculus VR (virtual reality).

The training is supported by a structured curriculum, delivered by specialist endovascular instructors with many years‘ clinical experience. The Program is targeted at specialist trainees in every year of their course, medical students (condensed course), and interested interventionists. The scope of the package includes EVAR for aneurysm repair, carotid, renal, iliac, femoral and tibial artery angioplasties. In addition, the curriculum includes training on emergency vascular cases such as ruptured aneurysms and visceral bleeding and trauma.

“The importance of periodical continuous education, training and structured curricula of interventional procedures has been confirmed by numerous clinical experts around the globe“, said CATHI Managing Director Marketing & Sales Manuela Werner. “With this joint venture between VSS and our company we are combining top level expertise with our near to reality simulation systems. We are very pleased to be cooperating with the very experienced vascular and endovascular surgeon Dr. Abdullah Jibawi.“

“We have built our curriculum with the end user in mind in every minute detail. We want to answer the real need for training by allowing a layer by layer build up of skills and decision making, associated with availability of performing procedure where and when the trainees feel so“, added Consultant Vascular Surgeon Dr Abdullah Jibawi. “Our program introduces the ability to train interventionists over a specified period of time, followed by a customised exposure to a specified product line to fine tune their experience as needed and required.“

The program is accredited by the Royal College of Surgeons of Edinburgh for Continuing professional development (CPD), valued at 12 CPD points.

SourceCATHI

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”